N/A
N=478
Drug Use Survey (DUS) of Triple Therapy (Methycobal (MBL)+ Myonal (MYO)+ Non-steroidal Anti-inflammatory Drags (NSAID)) on the Symptom Relief of Lumbar DDD in China
Lumbar Disc Degenerative Disease
Bottom Line
View on ClinicalTrials.gov: NCT01299077 ↗Enrolled (actual)
478
Serious AEs
0.0%
Results posted
Nov 2011
Primary outcome: Primary: Overall Satisfaction Degree After 2 Weeks Treatment of Triple Therapy (MBL+MYO+NSAID). — 91.21; 7.74; 1.05; 86.4 percentage of participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Eisai China Inc.
- Primary completion
- Sep 2010
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Overall Satisfaction Degree After 2 Weeks Treatment of Triple Therapy (MBL+MYO+NSAID). |
91.21; 7.74; 1.05; 86.4; 12.76; 0.84 | — |
| SECONDARY Onset Time of Symptom Relief. |
4.68 | — |
| SECONDARY Safety Data During Triple Therapy. |
2.7; 0 | — |
| SECONDARY Japanese Orthopedic Association (JOA) Score |
15.72; 21.28 | — |
| SECONDARY Visual Analogue Scale (VAS) Score |
6.23; 2.61 | — |
Summary
The purpose of this study is to observe the overall satisfaction of patients with degenerative disc disease after receiving triple therapy.
Eligibility Criteria
Inclusion criteria
- lumbar degenerative disc disease (DDD)
- patients who have been prescribed over 2 weeks of triple therapy
Exclusion criteria
Patients who do not meet inclusion criteria for DDD
Data sourced from ClinicalTrials.gov (NCT01299077). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.